S

Saniona AB (publ)

STO-SANION
Nasdaq Stockholm
Healthcare Biotechnology
Global Rank
#22747
Country Rank
#299
Market Cap
$127.89 M
Price
$0.94
Change (%)
1.59%
Volume
706,120

Saniona AB (publ)'s latest marketcap:

$127.89 M

As of 06/14/2025, Saniona AB (publ)'s market capitalization has reached $127.89 M. According to our data, Saniona AB (publ) is the 22747th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap $127.89 M
Revenue (ttm) $35.54 M
Net Income (ttm) $22.77 M
Shares Out 136.09 M
EPS (ttm) $0.2
Forward PE 0.00
Ex-Dividend Date n/a
Earnings Date 08/28/2025
Market Cap Chart
Data Updated: 06/14/2025

Saniona AB (publ)'s yearly market capitalization.

Saniona AB (publ) has seen its market value drop from kr1.28 B to kr127.89 M since 2020, representing a total decrease of 90.05% and an annual compound decline rate (CAGR) of 40.42%.
Date Market Cap Change (%) Global Rank
06/14/2025 kr127.89 M 32.51% 22747
12/30/2024 kr904.76 M 251.84% 24653
12/29/2023 kr257.15 M 34.48% 32277
12/30/2022 kr191.21 M -65.37% 33133
12/30/2021 kr552.11 M -57.03% 26360
12/30/2020 kr1.28 B 18093

Company Profile

About Saniona AB (publ)

Saniona AB (publ) is a clinical-stage biopharmaceutical company focused on researching, developing, and commercializing treatments for rare diseases. Headquartered in Glostrup, Denmark, the company operates in Sweden, Germany, Denmark, the United Kingdom, and Mexico.

Key Products & Pipeline

  • Tesofensine: A monoamine reuptake inhibitor in Phase 3 clinical trials for obesity treatment.
  • Tesomet: An oral investigational therapy in Phase 2b trials for hypothalamic obesity and Prader-Willi syndrome.
  • SAN711: A GABAA α3 modulator for absence seizures, completed Phase 1 trials.
  • SAN903: A novel calcium-activated potassium ion channel inhibitor for inflammatory bowel disease, in preclinical development.
  • SAN2219: A GABAA α2/α3/α5 modulator for acute repetitive seizures, in preclinical stage.
  • SAN2355: Targeting refractory focal onset seizures.
  • SAN2465: For major depressive disorder.
  • Additional programs for epilepsy, Alzheimer’s, schizophrenia, and migraine.

Strategic Collaborations

  • Partnership with Boehringer Ingelheim for therapeutic development.
  • License agreement with Productos Medix for tesofensine and Tesomet.
  • Research collaboration with Cephagenix ApS for migraine treatments.
  • Collaboration with AstronauTx for Alzheimer’s disease therapeutics.

Founded in 2011, Saniona AB (publ) continues to advance innovative treatments for unmet medical needs.

Frequently Asked Questions

  • What is Saniona AB (publ)'s (STO-SANION) current market cap?
    As of 06/14/2025, Saniona AB (publ) (including the parent company, if applicable) has an estimated market capitalization of $127.89 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
  • Saniona AB (publ) global market capitalization ranking is approximately 22747 as of 06/14/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.

MarketCapWatch.com ranks all listed companies worldwide, providing unique insights into market capitalization across industries. As one of the most comprehensive ranking platforms, it covers companies of all sizes and sectors.

Ranking
Community

Copyright © 2025. All rights reserved

Important Disclaimer: All content provided on this website, including hyperlinked pages, related applications, forums, blogs, social media accounts, and other platforms ("the Site"), is for general informational purposes only and sourced from third-party providers. We make no guarantees regarding the accuracy, completeness, or timeliness of the content.

None of the information presented constitutes financial, legal, or professional advice. Users should conduct their own research, evaluation, and verification before making any decisions. Investing and trading carry significant risks that may lead to substantial losses. Therefore, we strongly recommend consulting a qualified financial advisor before taking any action.